Mount Sinai Hospital

Mount Sinai Hospital

November 08, 2005 12:46 ET

Mount Sinai Hospital names new research director

Dr. Jim Woodgett appointed new Director of Samuel Lunenfeld Research Institute Attention: Assignment Editor, Business/Financial Editor, City Editor, Health/Medical Editor, Science Editor TORONTO, ONTARIO--(CCNMatthews - Nov. 8, 2005) - Dr. Jim Woodgett, an internationally recognized molecular biologist known for research breakthroughs in understanding the molecular mechanisms contributing to breast and colon cancers, has been named the new Director of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital.

"The Samuel Lunenfeld Research Institute is home to many of Canada's high impact medical researchers," said Dr. Woodgett. "Its past achievements are globally recognized and I look forward to building on its talent and reputation for scientific excellence."

Dr. Woodgett says there has never been a more exciting time in discovery and the bench to bedside translation of medical research into treatments and cures. He describes the scientists at the SLRI as "pioneers" in stem cell research, systems biology, molecular genetics and genomic medicine.

"My job is simply to 'best enable' these exceptional researchers to realize their ideas and to help promote a culture of research-based medicine both within the institute and Mount Sinai Hospital," said Dr. Woodgett.

Dr. Woodgett's appointment, effective November 4, 2005, comes at an exciting time for the SLRI which just celebrated Decades of Discovery, its 20th anniversary of scientific and medical discovery, said Joseph Mapa, President and Chief Executive Officer of Mount Sinai Hospital.

"We're at a tipping point where we - and our patients - are increasingly benefiting from the basic research our brilliant staff have been conducting at the world-renowned Samuel Lunenfeld Research Institute," said Mapa. "I am thrilled to welcome Jim at this exciting time and launch the next 20 years of scientific excellence at Mount Sinai Hospital."

Since 2000, Dr. Woodgett has served as Director of the University Health Network's (UHN) Microarray Centre. He has also been Division Head of Experimental Therapeutics at the Ontario Cancer Institute at UHN's Princess Margaret Hospital. His research interests span dissection of the signaling pathways that are subverted in breast and colon cancer, understanding the cell fate decisions of stem cells and the development of DNA microarray technologies that permit genome-wide analysis of gene activity.

About The Samuel Lunenfeld Research Institute
The Samuel Lunenfeld Research Institute of Mount Sinai Hospital, a University of Toronto affiliated research centre, was established in 1985. It is one of the world's leading centres in biomedical research. The Institute is committed to excellence in biomedical research and the training of young investigators. For more information about SLRI research, visit

About Mount Sinai Hospital
Mount Sinai Hospital is recognized nationally and internationally for its excellence in the provision of compassionate patient care, teaching and research. Its key priority programs are Women's and Infants' Health, Surgical Subspecialties and Oncology, Internal Medicine and Subspecialties, and the Samuel Lunenfeld Research Institute. It is a University of Toronto-affiliated patient care, teaching and research centre. Visit for more information about Mount Sinai Hospital.


Contact Information

  • Rob McCartney, Mount Sinai Hospital
    Primary Phone: 416-586-4800 ext. 7821